Hemgenix has long been offered ‘conditional authorisation’. Consequently the eu Medicines Agency made a decision that the advantages of Hemgenix are larger than its risks, but the company must offer more evidence just after authorisation.Gurus noted that the amount of sufferers envisioned to acquire etranacogene dezaparvovec in another three ye